547 related articles for article (PubMed ID: 25345753)
21. Targeting Inflammation Through a Physical Active Lifestyle and Pharmaceuticals for the Treatment of Type 2 Diabetes.
Knudsen SH; Pedersen BK
Curr Diab Rep; 2015 Oct; 15(10):82. PubMed ID: 26358738
[TBL] [Abstract][Full Text] [Related]
22. Cardiovascular metabolic syndrome - an interplay of, obesity, inflammation, diabetes and coronary heart disease.
Rana JS; Nieuwdorp M; Jukema JW; Kastelein JJ
Diabetes Obes Metab; 2007 May; 9(3):218-32. PubMed ID: 17391148
[TBL] [Abstract][Full Text] [Related]
23. [Molecular targets for new drug discovery to treat type 2 diabetes and obesity].
Bastarrachea RA; Montero JC; Saavedra-Gajardo I; Cerda-Flores R; Machado-Domínguez A; Comuzzie AG
Rev Med Chil; 2008 Jan; 136(1):107-17. PubMed ID: 18483661
[TBL] [Abstract][Full Text] [Related]
24. The metabolic syndrome - an ongoing story.
Duvnjak L; Duvnjak M
J Physiol Pharmacol; 2009 Dec; 60 Suppl 7():19-24. PubMed ID: 20388942
[TBL] [Abstract][Full Text] [Related]
25. Potential role of salicylates in type 2 diabetes.
Rumore MM; Kim KS
Ann Pharmacother; 2010; 44(7-8):1207-21. PubMed ID: 20516365
[TBL] [Abstract][Full Text] [Related]
26. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes.
Esser N; Legrand-Poels S; Piette J; Scheen AJ; Paquot N
Diabetes Res Clin Pract; 2014 Aug; 105(2):141-50. PubMed ID: 24798950
[TBL] [Abstract][Full Text] [Related]
27. C-reactive protein, its role in inflammation, Type 2 diabetes and cardiovascular disease, and the effects of insulin-sensitizing treatment with thiazolidinediones.
Nesto R
Diabet Med; 2004 Aug; 21(8):810-7. PubMed ID: 15270782
[TBL] [Abstract][Full Text] [Related]
28. Hepatic insulin resistance, metabolic syndrome and cardiovascular disease.
Meshkani R; Adeli K
Clin Biochem; 2009 Sep; 42(13-14):1331-46. PubMed ID: 19501581
[TBL] [Abstract][Full Text] [Related]
29. A high ratio of dietary n-3/n-6 polyunsaturated fatty acids improves obesity-linked inflammation and insulin resistance through suppressing activation of TLR4 in SD rats.
Liu HQ; Qiu Y; Mu Y; Zhang XJ; Liu L; Hou XH; Zhang L; Xu XN; Ji AL; Cao R; Yang RH; Wang F
Nutr Res; 2013 Oct; 33(10):849-58. PubMed ID: 24074743
[TBL] [Abstract][Full Text] [Related]
30. Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: effects of pioglitazone and metformin treatment.
Ciaraldi TP; Aroda V; Mudaliar SR; Henry RR
Metabolism; 2013 Nov; 62(11):1587-96. PubMed ID: 23958241
[TBL] [Abstract][Full Text] [Related]
31. The inflammatory consequences of psychologic stress: relationship to insulin resistance, obesity, atherosclerosis and diabetes mellitus, type II.
Black PH
Med Hypotheses; 2006; 67(4):879-91. PubMed ID: 16781084
[TBL] [Abstract][Full Text] [Related]
32. Novel C-C chemokine receptor 2 antagonists in metabolic disease: a review of recent developments.
Kang YS; Cha JJ; Hyun YY; Cha DR
Expert Opin Investig Drugs; 2011 Jun; 20(6):745-56. PubMed ID: 21466412
[TBL] [Abstract][Full Text] [Related]
33. The inflammatory status score including IL-6, TNF-α, osteopontin, fractalkine, MCP-1 and adiponectin underlies whole-body insulin resistance and hyperglycemia in type 2 diabetes mellitus.
Daniele G; Guardado Mendoza R; Winnier D; Fiorentino TV; Pengou Z; Cornell J; Andreozzi F; Jenkinson C; Cersosimo E; Federici M; Tripathy D; Folli F
Acta Diabetol; 2014 Feb; 51(1):123-31. PubMed ID: 24370923
[TBL] [Abstract][Full Text] [Related]
34. Targeting endothelial metaflammation to counteract diabesity cardiovascular risk: Current and perspective therapeutic options.
Potenza MA; Nacci C; De Salvia MA; Sgarra L; Collino M; Montagnani M
Pharmacol Res; 2017 Jun; 120():226-241. PubMed ID: 28408314
[TBL] [Abstract][Full Text] [Related]
35. Abdominal adiposity and cardiometabolic risk: do we have all the answers?
Haffner SM
Am J Med; 2007 Sep; 120(9 Suppl 1):S10-6; discussion S16-7. PubMed ID: 17720354
[TBL] [Abstract][Full Text] [Related]
36. [Type 2 diabetes and anti-inflammatory agents: new therapeutic prospects?].
Esser N; Paquot N; Scheen AJ
Rev Med Suisse; 2011 Aug; 7(306):1614-8, 1620. PubMed ID: 21972727
[TBL] [Abstract][Full Text] [Related]
37. Dietary capsaicin reduces obesity-induced insulin resistance and hepatic steatosis in obese mice fed a high-fat diet.
Kang JH; Goto T; Han IS; Kawada T; Kim YM; Yu R
Obesity (Silver Spring); 2010 Apr; 18(4):780-7. PubMed ID: 19798065
[TBL] [Abstract][Full Text] [Related]
38. [Inflammation and diabetes].
Löbner K; Füchtenbusch M
MMW Fortschr Med; 2004 Sep; 146(35-36):32-3, 35-6. PubMed ID: 15540536
[TBL] [Abstract][Full Text] [Related]
39. Metabolic syndrome: nature, therapeutic solutions and options.
Onat A
Expert Opin Pharmacother; 2011 Aug; 12(12):1887-1900. PubMed ID: 21756201
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
Yamagishi S; Nakamura K; Takeuchi M
Med Hypotheses; 2005; 65(1):152-4. PubMed ID: 15893133
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
